Opportunity Information: Apply for RFA HL 12 008
Apply for RFA HL 12 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Translational Research Centers in Thrombotic and Hemostatic Disorders (TRC THD) (U54)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Nov 16, 2010 and posted on Nov 16, 2010.
- Applicants must submit their applications by Apr 1, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $14,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Independent school districts Private institutions of higher education Public housing authorities/Indian housing authorities County governments Public and State controlled institutions of higher education Small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments For profit organizations other than small businesses Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Translational Research Centers in Thrombotic and Hemostatic Disorders (TRC THD) (U54) funding opportunity, issued by the National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health, is a discretionary cooperative agreement program designed to push promising discoveries in blood clotting and bleeding disorders toward real-world clinical use. The central aim is to close the gap between basic laboratory findings and practical tools that improve prevention, diagnosis, and treatment of thrombotic and hemostatic disorders. In other words, the program is meant for research teams that are ready to move beyond discovery science and into early translational work where a concept starts becoming something clinicians and patients could ultimately benefit from.
This initiative supports multiple-project research Centers, meaning each funded award is expected to be a coordinated hub rather than a single standalone project. Each Center must be driven by important, clearly stated clinical questions in thrombosis and hemostasis, and it must include at least one tangible translational element already positioned for early-stage development. The announcement specifically calls out the expectation that a Center include at least one assay, method, procedure, or agent that is in early phase translation. That requirement signals that NHLBI is looking for programs with a concrete translational pipeline, such as developing and validating a diagnostic assay, refining a clinical or laboratory procedure, advancing a therapeutic candidate, or building a method that can be tested and adopted in clinical research settings.
A defining feature of the TRC THD program is its emphasis on integrating applied and basic science. Rather than separating mechanistic research from product-oriented development, the Centers are expected to combine these approaches so that laboratory insights inform development decisions and early translational results feed back into improved biological understanding. The overall goal is to accelerate the movement of discoveries toward clinical application, which can include generating the kinds of data and operational readiness needed for subsequent clinical studies, broader validation, or later-stage development.
The program also requires a translational research skills development component. This means each Center is expected to do more than produce scientific outputs; it should actively build and strengthen the workforce and skill sets needed for translational research in thrombotic and hemostatic diseases. While the announcement does not prescribe a single format in the provided text, this component generally implies structured training, mentorship, and hands-on opportunities that prepare investigators to navigate the specialized demands of translational work, such as assay development and validation, regulatory considerations, reproducibility, team science, and the practical steps required to move candidates into clinical evaluation.
Another core expectation is collaboration with Clinical and Translational Science Awards (CTSA) programs or comparable institutional programs that provide similar capabilities. The intent is to leverage existing infrastructure and resources that can speed translation, such as clinical research support, biostatistics, regulatory guidance, clinical trial readiness resources, participant recruitment infrastructure, core laboratories, informatics, and other shared services. By requiring these collaborations, NHLBI is signaling that successful Centers should be embedded in an ecosystem that can rapidly turn promising early-stage advances into well-supported translational studies rather than rebuilding those capabilities from scratch.
Administratively, the opportunity is identified as Funding Opportunity Number RFA-HL-12-008, using the U54 activity code and structured as a cooperative agreement. A cooperative agreement typically indicates substantial federal scientific or programmatic involvement compared with a standard grant mechanism, reflecting the expectation of active coordination between NHLBI and awardees in shaping progress and ensuring that the Centers meet the translational objectives of the program. The activity category is Health, and it is associated with CFDA number 93.839, Blood Diseases and Resources Research. The program explicitly states there is no cost sharing or matching requirement.
In terms of scale and timing, the opportunity was posted on November 16, 2010, with an original and current closing date of April 1, 2011, and an archive date of May 2, 2011. The estimated total funding listed is $14,000,000, indicating an intention to support a meaningful set of Center awards with enough resources to run coordinated, multi-component translational programs.
Eligibility is broad and includes a wide range of domestic organizational types, spanning public and private institutions of higher education, nonprofit organizations with and without 501(c)(3) status, small businesses, for-profit organizations other than small businesses, and multiple levels of government entities (state, county, city or township, special district), as well as public housing authorities/Indian housing authorities. The eligibility language also explicitly includes several categories of institutions and organizations often referenced in federal funding announcements, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, tribal governments (federally recognized and other than federally recognized), regional organizations, and U.S. territories or possessions. This breadth suggests NHLBI intended to encourage participation from diverse institutions and communities, provided applicants can assemble the required translational capabilities and collaborations.
For applicants seeking the complete announcement and official details, the funding notice is available through the NIH grants guide at the listed link (http://grants.nih.gov/grants/guide/rfa_files/RFA_HL_12_008.html), and NHLBI referenced an FAQ page for additional clarifications (as provided in the description). The contact information included in the source text points to the NIH Office of Extramural Research (OER) Webmaster for technical difficulties accessing the announcement.
Frequently Asked Questions (FAQs): Translational Research Centers in Thrombotic and Hemostatic Disorders (TRC THD) (U54)
What is the TRC THD (U54) funding opportunity?
The Translational Research Centers in Thrombotic and Hemostatic Disorders (TRC THD) (U54) is a discretionary cooperative agreement funding opportunity issued by the National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health (NIH). It is designed to move promising discoveries in blood clotting and bleeding disorders toward real-world clinical use.
What is the main goal of this program?
The central goal is to close the gap between basic laboratory findings and practical tools that improve prevention, diagnosis, and treatment of thrombotic and hemostatic disorders. The focus is on early translational work, where discoveries begin to take a form that can ultimately benefit clinicians and patients.
What types of research does this opportunity emphasize?
This program emphasizes translational research in thrombotic and hemostatic disorders, specifically research that goes beyond discovery science and advances tangible tools and approaches toward clinical application.
Does this funding support a single project or a larger Center structure?
This opportunity supports multiple-project research Centers. Each funded award is expected to function as a coordinated hub (a Center) rather than a single standalone project.
What must drive the research agenda for each Center?
Each Center must be driven by important, clearly stated clinical questions in thrombosis and hemostasis, with research organized to address those clinically relevant questions.
Is a translational component required, and what qualifies?
Yes. Each Center is expected to include at least one translational element already positioned for early-stage development. The opportunity specifically anticipates at least one assay, method, procedure, or agent in early phase translation.
What are examples of the types of translational elements NHLBI is looking for?
Examples described include developing and validating a diagnostic assay, refining a clinical or laboratory procedure, advancing a therapeutic candidate, or building a method that can be tested and adopted in clinical research settings.
How does the program expect basic science and applied development to work together?
A defining feature is integration of applied and basic science. Centers are expected to combine mechanistic research with product- or tool-oriented development so that laboratory insights inform development decisions and early translational results feed back into improved biological understanding.
What does "early translational" work mean in the context provided?
Based on the description, early translational work refers to activities that move a concept beyond discovery and toward clinical readiness, such as generating data and operational readiness needed for subsequent clinical studies, broader validation, or later-stage development.
Is workforce or skills training part of the requirements?
Yes. The program requires a translational research skills development component. Each Center is expected to build and strengthen the workforce and skill sets needed for translational research in thrombotic and hemostatic diseases.
What kinds of skills development are implied by the opportunity description?
While the provided text does not prescribe a single format, it indicates structured training, mentorship, and hands-on opportunities that prepare investigators for translational work, including areas such as assay development and validation, regulatory considerations, reproducibility, team science, and practical steps to move candidates into clinical evaluation.
Is collaboration with CTSA programs required?
Yes. Another core expectation is collaboration with Clinical and Translational Science Awards (CTSA) programs or comparable institutional programs with similar capabilities.
Why does the opportunity require CTSA or comparable collaborations?
The intent is to leverage existing infrastructure that can speed translation, such as clinical research support, biostatistics, regulatory guidance, clinical trial readiness resources, participant recruitment infrastructure, core laboratories, informatics, and other shared services.
What is the funding mechanism and what does it imply?
The mechanism is a U54 cooperative agreement. The description notes that a cooperative agreement typically involves substantial federal scientific or programmatic involvement compared with a standard grant mechanism, reflecting active coordination between NHLBI and awardees to shape progress and ensure Centers meet translational objectives.
What is the Funding Opportunity Number for this announcement?
The Funding Opportunity Number is RFA-HL-12-008.
What is the associated CFDA number and program category?
The opportunity is associated with CFDA 93.839 (Blood Diseases and Resources Research). The activity category is Health.
Is cost sharing or matching required?
No. The program explicitly states there is no cost sharing or matching requirement.
When was the opportunity posted, and what were the key dates?
The opportunity was posted on November 16, 2010. The original and current closing date listed is April 1, 2011. The archive date is May 2, 2011.
How much total funding was estimated for this opportunity?
The estimated total funding listed is $14,000,000, indicating support for a meaningful set of Center awards with enough resources to run coordinated, multi-component translational programs.
Who is eligible to apply?
Eligibility is broad and includes many domestic organizational types such as public and private institutions of higher education, nonprofit organizations (with and without 501(c)(3) status), small businesses, for-profit organizations other than small businesses, and government entities (state, county, city or township, special district), as well as public housing authorities/Indian housing authorities.
Are specific types of institutions and communities explicitly included in eligibility?
Yes. The eligibility language explicitly includes categories commonly referenced in federal announcements, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, tribal governments (federally recognized and other than federally recognized), regional organizations, and U.S. territories or possessions.
Where can applicants find the complete official announcement?
The complete announcement is available through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa_files/RFA_HL_12_008.html.
Is there an official FAQ resource referenced for additional clarifications?
Yes. NHLBI referenced an FAQ page for additional clarifications (as noted in the provided description).
Who is the listed contact for technical difficulties accessing the announcement?
The contact information included points to the NIH Office of Extramural Research (OER) Webmaster for technical difficulties accessing the announcement.
What makes a Center competitive based on the stated expectations?
Based on the provided information, the program expects Centers to: (1) focus on clearly stated clinical questions in thrombosis and hemostasis, (2) include at least one concrete early translational element (assay, method, procedure, or agent), (3) integrate basic and applied science, (4) include a translational research skills development component, and (5) collaborate with CTSA programs or comparable infrastructure to accelerate translation.
Browse more opportunities from the same category: Health
Next opportunity: NIDCR Behavioral or Social Intervention Planning and Pilot Data Grant (R34)
Previous opportunity: Catalyzing New International Collaborations
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDCR Behavioral or Social Intervention Planning and Pilot Data Grant (R34) Apply for RFA DE 12 001 Funding Number: RFA DE 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Translational Tools for Clinical Studies of Mind/Body and Manual Therapy CAM Interventions (R01) Apply for RFA AT 11 003 Funding Number: RFA AT 11 003 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Functional Genetics, Epigenetics, and Non coding RNAs in Drug Addiction (R01) Apply for PA 11 033 Funding Number: PA 11 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Institutional Collaboration Between The Institute Pasteur Of Madagascar And The Centers For Disease Control And Prevention On Malaria And Vector Borne Diseases (U01) Apply for RFA GH 11 003 Funding Number: RFA GH 11 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01) Apply for RFA AA 11 006 Funding Number: RFA AA 11 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrated Health Social Marketing Program for Mozambique Apply for 656 11 001 Funding Number: 656 11 001 Agency: Mozambique USAID Maputo Category: Health Funding Amount: $20,557,019 |
| Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Resource and Support Cores (U24) Apply for RFA AA 11 007 Funding Number: RFA AA 11 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Social Science Research in Population and Reproductive Health Apply for APS OAA 10 000002 Funding Number: APS OAA 10 000002 Agency: Agency for International Development Category: Health Funding Amount: $5,000,000 |
| Sustainable Leadership, Managment and Governance RFA Apply for SOL OAA 11 000009 Funding Number: SOL OAA 11 000009 Agency: Agency for International Development Category: Health Funding Amount: $200,000,000 |
| Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) Study to Explore Early Development (SEED) II (U01) Apply for RFA DD 11 002 Funding Number: RFA DD 11 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $900,000 |
| Pilot Longitudinal Data Collection to inform Public Health Fragile X Syndrome Apply for RFA DD 11 007 Funding Number: RFA DD 11 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| National Institute on Aging Revision Requests for Active Cooperative Agreements (U01) Apply for PAR 11 042 Funding Number: PAR 11 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Family History and Diamond Blackfan Anemia (U01) Apply for RFA DD 11 010 Funding Number: RFA DD 11 010 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| School Mental Health Program and Policy Analysis Center Apply for HRSA 11 106 Funding Number: HRSA 11 106 Agency: Health Resources and Services Administration Category: Health Funding Amount: $450,000 |
| Sickle Cell Disease and Newborn Screening Program and National Coordination and Evaluation Center Apply for HRSA 11 031 Funding Number: HRSA 11 031 Agency: Health Resources and Services Administration Category: Health Funding Amount: $700,000 |
| Reducing New HIV Infections, Strengthening Health And Strategic Information Systems, Capacity Building And Increasing Access To Quality HIV/AIDS Services Through Support Programs Conducted By The Government Of Botswana Under PEPFAR Apply for CDC RFA GH11 1197 Funding Number: CDC RFA GH11 1197 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $23,000,000 |
| Centers without Walls for Collaborative Research in the Epilepsies Genetics and Genomics of Human Epilepsies (U01) Apply for RFA NS 11 007 Funding Number: RFA NS 11 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Basic Behavioral and Social Science Opportunity Network (OppNet) Short term Mentored Career Development Awards in the Basic Behavioral and Social Sciences for Mid career and Senior Investigators (K18) Apply for RFA DE 11 003 Funding Number: RFA DE 11 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Genomic Research Grant on Integrative Data Analysis for Vision Research (R01) Apply for RFA EY 11 001 Funding Number: RFA EY 11 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Genetics in Primary Care Apply for HRSA 11 136 Funding Number: HRSA 11 136 Agency: Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.